دورية أكاديمية

Use of GELSECTAN® in Patients with Irritable Bowel Syndrome (IBS): an Italian Experience.

التفاصيل البيبلوغرافية
العنوان: Use of GELSECTAN® in Patients with Irritable Bowel Syndrome (IBS): an Italian Experience.
المؤلفون: Bellini, Massimo, Berti, Ginevra, Bonfrate, Leonilde, Ciranni, Flavia, Ciaula, Agostino Di, Ruscio, Mirko Di, Dell'Era, Alessandra, Lambiase, Christian, Noto, Antonino, Pancetti, Andrea, Portincasa, Piero, Rettura, Francesco
المصدر: Patient Preference & Adherence; Aug2021, Vol. 15, p1763-1774, 12p
مصطلحات موضوعية: IRRITABLE colon, LABOR productivity, PHYSICIANS, PEA proteins, QUALITY of life, ADULTS
مستخلص: Irritable bowel syndrome is a chronic functional gastrointestinal disorder characterized by recurrent chronic abdominal pain and impaired bowel habits, which affects daily activity and work productivity, and is associated with a significant healthcare economic burden as well as an impaired quality of life and psycho-affective profile. Management of patients is a great challenge for physicians; at the present, the therapeutic strategy aimed to treat the different symptoms, and no medical therapy is proven to modify the natural history of the disease. GELSECTAN® (xyloglucan, pea protein and tannins, xylo-oligosaccharides) is a medical device with both protective and prebiotic actions on the intestinal mucosa, able to restore intestinal permeability and to improve gastrointestinal symptoms, controlling diarrhoea, abdominal pain and bloating in adult patients with irritable bowel syndrome. We report and discuss four cases of different patients with irritable bowel syndrome successfully managed with Gelsectan in the real clinical practice. Literature data, as well as these case reports, show that this device is effective and safe in improving symptoms and bowel habits associated to irritable bowel syndrome; its efficacy and safety were confirmed for the long-term use too. Agents with film-forming protective properties, such as Gelsectan, represent a new alternative therapeutic option for the management of patients with irritable bowel syndrome. [ABSTRACT FROM AUTHOR]
Copyright of Patient Preference & Adherence is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:1177889X
DOI:10.2147/PPA.S318859